{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:00:31Z","timestamp":1783393231328,"version":"3.54.6"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/130\/94"],"award-info":[{"award-number":["15\/130\/94"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical haemolytic uraemic syndrome (aHUS) is a rare but severe condition caused by complement dysregulation. Eculizumab prophylaxis prevents recurrence and improves survival, yet the benefits of lifelong treatment for patients are uncertain and the long-term costs for health services are substantial. This economic evaluation applied the results from the Stopping Eculizumab Treatment Safely in aHUS (SETS aHUS) trial and assessed the cost-effectiveness of replacing lifelong eculizumab with a disease monitoring strategy over the long term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was used to estimate cost and quality-adjusted life years (QALYs) for a treatment withdrawal and disease monitoring strategy over the long term. Results from the SETS aHUS trial informed the risk of relapse diagnosis or progression, utility values and additional healthcare use. Time to relapse diagnosis was extrapolated using parametric survival functions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The treatment withdrawal and disease monitoring strategy increased average patient QALYs by 0.08 [95% credible interval (CrI) \u22120.33\u20130.53], and reduced patient costs by \u00a34\u00a0234\u00a0196 (95% CrI \u2212\u00a3684\u00a0495 to \u2212\u00a36\u00a0403\u00a0694) compared with the lifelong delivery of eculizumab. The impact on survival estimates was low, as withdrawal patients had an average reduction of 0.0005 patient life years (LYs) (95% CrI \u22120.0029\u20130) over an 80-year time horizon. Withdrawal and monitoring had a 64% likelihood of being more effective and less costly than lifelong treatment. Results remained robust across multiple scenarios exploring uncertainties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment withdrawal and disease monitoring was cost-effective compared with lifelong eculizumab therapy. Its adoption is expected to substantially reduce costs per patient and may improve average patient quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf166","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:31:45Z","timestamp":1755603105000},"page":"321-331","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-7318","authenticated-orcid":false,"given":"Giovany","family":"Orozco-Leal","sequence":"first","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]},{"name":"London School of Hygiene and Tropical Medicine, London Department of Health Services Research and Policy, ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemi","family":"Oluboyede","sequence":"additional","affiliation":[{"name":"Putnam Associates LLC, Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Brocklebank","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Bryant","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dunn","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Johnson","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]},{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lecouturier","sequence":"additional","affiliation":[{"name":"Middlesbrough Council, Middlesbrough ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Weetman","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Wong","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Woodward","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"aHUS Alliance Global Action ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S","family":"Sheerin","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"aHUS Alliance Global Action ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2026013001370850500_bib1","doi-asserted-by":"publisher","first-page":"e054536","DOI":"10.1136\/bmjopen-2021-054536","article-title":"Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study","volume":"12","author":"Dunn","year":"2022","journal-title":"BMJ Open"},{"key":"2026013001370850500_bib2","volume-title":"Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"2026013001370850500_bib3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026013001370850500_bib4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"2026013001370850500_bib5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2026013001370850500_bib6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1740774509105221","article-title":"Bayesian design of single-arm phase II clinical trials with continuous monitoring","volume":"6","author":"Johnson","year":"2009","journal-title":"Clin Trials"},{"key":"2026013001370850500_bib7","volume-title":"Information for authors","author":"National Institute for Health and Care Research"},{"key":"2026013001370850500_bib8","first-page":"101148","article-title":"Stopping eculizumab treatment safely in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome","volume":"48","author":"Bryant","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026013001370850500_bib9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J Med Econ"},{"key":"2026013001370850500_bib10","doi-asserted-by":"publisher","first-page":"i115","DOI":"10.1093\/ndt\/gfw353","article-title":"Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome","volume":"32","author":"van den Brand","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026013001370850500_bib11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026013001370850500_bib12","article-title":"Company evidence submission for ravulizumab for treating atypical haemolytic uremic syndrome (aHUS) [ID1530]","author":"Alexion Pharmaceuticals"},{"key":"2026013001370850500_bib13","article-title":"Atypical haemolytic uraemic syn-drome (aHUS)\u2014eculizumab: evaluation report. Submission by the technology manufacturer\u2014Alexion, 2015. https:\/\/www.nice.org.uk\/guidance\/hst1\/documents\/committee-papers-2","author":"Alexion Pharmaceuticals"},{"key":"2026013001370850500_bib14","article-title":"Estimated glomerular filtration rate (eGFR)","author":"National Kidney Foundation"},{"key":"2026013001370850500_bib15","article-title":"NICE DSU Technical Support Document 14. Survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data","author":"Latimer","year":"2011"},{"key":"2026013001370850500_bib16","volume-title":"Ravulizumab for atypical haemolytic uremic syndrome: a single technology appraisal","author":"Nikolaidis"},{"key":"2026013001370850500_bib17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"2026013001370850500_bib18","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"2026013001370850500_bib19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2026013001370850500_bib20","article-title":"EQ-5D-5L","author":"EuroQol Group"},{"key":"2026013001370850500_bib21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","article-title":"Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study","volume":"41","author":"Hern\u00e1ndez Alava","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"2026013001370850500_bib22","volume-title":"Estimating EQ-5D by age and sex for the UK","author":"Hern\u00e1ndez Alava","year":"2022"},{"key":"2026013001370850500_bib23","author":"National Institute for Health and Care Excellence","journal-title":"British National Formulary (BNF)"},{"key":"2026013001370850500_bib24","article-title":"Following approval of eculizumab","author":"National Renal Complement Therapeutics Centre"},{"key":"2026013001370850500_bib25","article-title":"Ravulizumab for treating atypical haemolytic uraemic syndrome. Technology appraisal guidance","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"2026013001370850500_bib26","volume-title":"National tariff payment system documents, annexes and supporting documents","author":"NHS England"},{"key":"2026013001370850500_bib27","volume-title":"Unit costs of health and social care 2022 manual","author":"Jones","year":"2023"},{"key":"2026013001370850500_bib28","volume-title":"NICE health technology evaluations: the manual; NICE process and methods","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"2026013001370850500_bib29","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economics evaluations","author":"Briggs","year":"2006"},{"key":"2026013001370850500_bib30","article-title":"Drugs and pharmaceutical electronic market information tool (eMIT)","author":"Department of Health and Social Care","year":"2023"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf166\/64110979\/gfaf166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/2\/321\/64110979\/gfaf166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/2\/321\/64110979\/gfaf166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:37:18Z","timestamp":1769755038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/2\/321\/8239797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,22]]},"published-print":{"date-parts":[[2026,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf166","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,8,22]]}}}